Clinical follow-up of 102 anti-Ro/SSA-positive patients with dermatological manifestations

Acta Dermato-Venereologica

Volumn 88, Issue 4, 2008, Pages 370-375

  Popovic, Karin ^a   Wahren Herlenius, Marie ^b   Nyberg, Filippa ^a  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Follow up; Ro SSA autoantibodies; Sj gren's syndrome; SLE; Subacute cutaneous lupus erythematosus

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; CALCIUM ANTAGONIST; CALCIUM PHOSPHATE; CHLORAMBUCIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LANSOPRAZOLE; LEUPRORELIN; METHOTREXATE; MINERAL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATRIUMAUROTHIOMALATE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; RANITIDINE; RITUXIMAB; RO ANTIBODY; THIAZIDE DIURETIC AGENT; VITAMIN;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SELF REPORT; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; SKIN MANIFESTATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRALGIA; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; RIBONUCLEOPROTEINS; RNA, SMALL CYTOPLASMIC; SKIN DISEASES;

EID: 47749115758     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0473     Document Type: Article

References (29)

1. Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 1979; 115: 1409-1415.
2. Srivastava M, Rencic A, Diglio G, Santana H, Bonitz P, Watson R, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol 2003; 139: 45-49.
3. Salomonsson S, Dorner T, Theander E, Bremme K, Larsson P, Wahren-Herlenius M. A serologic marker for fetal risk of congenital heart block. Arthritis Rheum 2002; 46: 1233-1241.
4. Salomonsson S, Sonesson SE, Ottosson L, Muhallab S, Olsson T, Sunnerhagen M, et al. Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 2005; 201: 11-17.
5. Fritzler MJ, Pauls JD, Kinsella TD, Bowen TJ. Antinuclear, anticytoplasmic, and anti-Sjogren's syndrome antigen A (SS-A/Ro) antibodies in female blood donors. Clin Immunol Immunopathol 1985; 36: 120-128.
6. de Vlam K, De Keyser F, Verbruggen G, Vandenbossche M, Vanneuville B, D'Haese D, et al. Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin Exp Rheumatol 1993; 11: 393-397.
7. Simmons-O'Brien E, Chen S, Watson R, Antoni C, Petri M, Hochberg M, et al. One hundred anti-Ro (SS-A) antibody positive patients: a 10-year follow-up. Medicine (Baltimore) 1995; 74: 109-130.
8. Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort. Arthritis Rheum 1995; 38: 1492-1499.
9. Mosca M, Neri R, Bencivelli W, Tavoni A, Bombardieri S. Undifferentiated connective tissue disease: analysis of 83 patients with a minimum follow-up of 5 years. J Rheumatol 2002; 29: 2345-2349.
10. Popovic K, Brauner S, Ek M, Wahren-Herlenius M, Nyberg F. Fine specificity of the Ro/SSA-autoantibody response in relation to serological and clinical findings in 96 patients with self-reported cutaneous symptoms induced by the sun. Lupus 2007; 16: 10-17.
11. Popovic K, Nyberg F, Wahren-Herlenius M, Nyberg F. A serology-based approach combined with clinical examination of 125 Ro/SSA-positive patients to define incidence and prevalence of subacute cutaneous lupus erythematosus. Arthritis Rheum 2007; 56: 255-264.
12. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25: 1271-1277.
13. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-558.
14. Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 1999; 17: 615-620.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
16. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-347.
17. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. Am Acad Dermatol 1981; 4: 471-475.
18. Sontheimer RD. Subacute cutaneous lupus erythematosus: a decade's perspective. Med Clinics N Am 1989; 73: 1073-1090.
19. Callen JP, Klein J. Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and therapeutic considerations in seventy-two patients. Arthritis Rheum 1988; 31: 1007-1013.
20. Healy E, Kieran E, Rogers S. Cutaneous lupus erythematosus - a study of clinical and laboratory prognostic factors in 65 patients. Ir J Med Sci 1995; 164: 113-115.
21. Millard LG, Rowell NR. Abnormal laboratory test results and their relationship to prognosis in discoid lupus erythematosus. A long-term follow-up study of 92 patients. Arch Dermatol 1979; 115: 1055-1058.
22. Tebbe B, Mansmann U, Wollina U, Auer-Grumbach P, Licht-Mbalyohere A, Arensmeier M, et al. Markers in cutaneous lupus erythematosus indicating systemic involvement. A multicenter study on 296 patients. Acta Derm Venereol 1997; 77: 305-308.
23. Zachariae H, Zachariae R, Blomqvist K, Davidsson S, Molin L, Mork C, et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 2002; 82: 108-113.
24. Cockayne SE, Glet RJ, Gawkrodger DJ, McDonagh AJ. Severe erythrodermic reactions to the proton pump inhibitors omeprazole and lansoprazole. Br J Dermatol 1999; 141: 173-175.
25. Bracke A, Nijsten T, Vandermaesen J, Meuleman L, Lambert J. Lansoprazole-induced subacute cutaneous lupus erythematosus: two cases. Acta Derm Venereol 2005; 85: 353-354.
26. Khan AJ, Marghoob AA, Prestia AE, Spector IJ. Methotrexate and the photodermatitis reactivation reaction: a case report and review of the literature. Cutis 2000; 66: 379-382.
27. Wenzel J, Brahler S, Bauer R, Bieber T, Tuting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol 2005; 153: 157-162.
28. Praprotnik S, Bozic B, Kveder T, Rozman B. Fluctuation of anti-Ro/SS-A antibody levels in patients with systemic lupus erythematosus and Sjogren's syndrome: a prospective study. Clin Exp Rheumatol 1999; 17: 63-68.
29. Hassan AB, Lundberg IE, Isenberg D, Wahren-Herlenius M. Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. Scand J Rheumatol 2002; 31: 133-139.